---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-040458"
form_type: "8-K"
ticker: "APTN"
cik: "0001938571"
company_name: "ADAPTIN BIO, INC."
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:26:37.223976+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adaptin Bio shares approved for OTCQB quotation under ticker APTN

## Summary
- Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.
- Trading expected to begin within the next 6-8 weeks, pending any material updates.
- CEO notes lead program APTN-101 is expected to begin a Phase 1 first-in-human trial shortly.
- Company develops precision cancer therapeutics targeting brain and difficult-to-reach tissues.

## SEC filing metadata
- accession: 0001213900-26-040458
- form_type: 8-K
- ticker: APTN
- cik: 0001938571
- company_name: ADAPTIN BIO, INC.
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/0001213900-26-040458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/ea0285223-8k_adaptin.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-040458
- JSON: https://secwatch.observer/filing/0001213900-26-040458.json
- Plain text: https://secwatch.observer/filing/0001213900-26-040458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.